Associate Professor Borislava Mihaylova
- Health Economics Research Centre
Borislava (Boby) Mihaylova is an Associate Professor and Senior Health Economist at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England: A Modeling Study.
Alonso S. et al, (2021), Hypertension
Long-term health outcomes of people with reduced kidney function in the UK: a modelling study using population health data
SCHLACKOW I. et al, (2020), PLoS Medicine
Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009-2017
Thalmann I. et al, (2020), EUROPEAN HEART JOURNAL, 41, 3509 - 3509
Real world cost and health outcomes of patients presented with chest pain in England: which is the most cost-effective first-line test?
Tsiachristas A. et al, (2020), EUROPEAN HEART JOURNAL, 41, 3547 - 3547
The Case for Early Identification and Intervention of Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Shlipak MG. et al, (2020), Kidney Int